Advertisement

Topics

Clinical Trials About "17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer" RSS

11:49 EDT 14th August 2018 | BioPortfolio

We list hundreds of Clinical Trials about "17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer" on BioPortfolio

We have published hundreds of 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer news stories on BioPortfolio along with dozens of 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Clinical Trials and PubMed Articles about 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Companies in our database. You can also find out about relevant 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Drugs and Medications on this site too.

Showing "Treating Patients With Inoperable Locoregionally Advanced Metastatic Thyroid" Clinical Trials 1–25 of 20,000+

Extremely Relevant

17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

RATIONALE: Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well 17-AAG works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer.


Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.


Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or metastatic thyroid cancer that did not respond to iodine therapy.

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies.

Thyroid Cancer and Sunitinib

Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this study, THYSU, is justified to evaluate the efficacy of sunitinib in metastatic thyroid carcinoma. Furthermore, the standard treatment of metastatic thyroid carcinoma when a general treatment is to be prescribed is limited to radioiodine. When radioiodi...

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.

TPF+CCRT vs.CCRT+PF in Locoregionally Advanced Nasopharyngeal Carcinoma

To see the effect of induction chemotherapy(TPF) followed by chemoradiotherapy VS concurrent chemoradiotherapy collowed by adjuvant chemotherapy (PF) inin treating with locoregionally advanced nasopharyngeal carcinoma (NPC).

Relevant

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.

Cyclophosphamide for Nasopharyngeal Carcinoma

There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). We investigated the efficacy and safety of metronomic oral cyclophosphamide as third-line treatment or beyond.

Phase Ⅲ Trial Adjuvant Chemotherapy in Patients With Locoregionally Advanced NPC

To see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating with locoregionally advanced nasopharyngeal carcinoma(NPC).

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor and by carrying tumor-killing substances directly to thyroid cancer cells.

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.

Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer

This study will enroll subjects with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A subjects will receive BGB-290; in Arm B subjects will receive placebo. The purpose of this study is to show that BGB-290 (versus placebo) will improve progression-free survival (PFS) in subjects with advanced or inoperable gastric cancer.

Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.

Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid cancer.

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Metastatic or Inoperable Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (Cancer)

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving oxaliplatin together with irinotecan and capecitabine works in treating patients with metastatic or inoperable locally advanced gastric cancer or gastroesophageal junction adenocarci...

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroi...

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

RATIONALE: Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or ...


More From BioPortfolio on "17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer"

Advertisement
Quick Search
Advertisement
Advertisement